Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + irinotecan + leucovorin + 5-fluorouracil + capecitabine + S-1-Chinese Academy of Medical Sciences-colorectal cancer
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This triplet chemotherapy regimen is a neoadjuvant treatment strategy being evaluated by the Chinese Academy of Medical Sciences for patients with resectable, locally advanced colorectal cancer (specifically stage IIIb/T4N2M0). The regimen consists of oxaliplatin (a platinum-based antineoplastic agent that forms DNA crosslinks) and irinotecan (a topoisomerase I inhibitor), combined with a fluoropyrimidine backbone. The fluoropyrimidine component is flexible within the study protocol, allowing for the administration of either intravenous 5-fluorouracil with leucovorin (folinic acid), or oral alternatives such as capecitabine or S-1. By combining three active cytotoxic agents, the regimen aims to maximize tumor shrinkage and improve surgical outcomes in the neoadjuvant setting.
- Other names
- Triplet chemotherapy regimen (oxaliplatin, irinotecan, and a fluoropyrimidine)Neoadjuvant triplet chemotherapy
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNADPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on oxaliplatin + irinotecan + leucovorin + 5-fluorouracil + capecitabine + S-1-Chinese Academy of Medical Sciences-colorectal cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + irinotecan + leucovorin + 5-fluorouracil + capecitabine + S-1-Chinese Academy of Medical Sciences-colorectal cancer.